Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?

The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exceptional.

Pipeline momentum since 2025: How the surge in preclinical and early clinical in vivo programmes is reshaping target selection, platform choice and development timelines and where early friction is already informing smarter design.

Indications set the limits (and the upside): Where clinicians are seeing real promise today for in vivo approaches (solid tumours, gastric cancers, sarcoma, liver and CNS), and where biology or delivery still constrains reach.

Portfolio decisions, not modality wars: How investors and big pharma are balancing in vivo alongside ex vivo strategies—and what this signals about future modality mix, sequencing and coexistence.